(Reuters) - Johnson & Johnson reported first-quarter revenue above analysts’ estimates on Tuesday, driven partly by demand for its Stelara treatment for psoriasis and Crohn’s disease and cancer drugs Darzalex and Imbruvica.
J&J, the first major drugmaker to report first-quarter results, reported a slight rise in quarterly sales to $20.02 billion, above the average analyst estimate of $19.61 billion, according to IBES data from Refinitiv.
The U.S. healthcare conglomerate said net profit fell to $3.75 billion, or $1.39 per share, from $4.37 billion, or $1.60 per share, a year earlier.
J&J recorded litigation expense of $423 million in the first quarter. The company not record litigation expense in the year-ago period.
Reporting by Manas Mishra and Saumya Sibi Joseph in Bengaluru; Editing by Saumyadeb Chakrabarty